Global

Harold Hambrose explains why applying user-centric design to healthcare business systems can save money and lives.

March 24, 2010.

Proving that one good turn deserves another, Pfizer and GlaxoSmithKline announced that they would provide millions of doses of pneumonia vaccines to some of the world's most impoverished countries at massive discounts.

A new report from IMS Health bumps the number of emerging markets to 17 and predicts that these nations will account for $90 billion in sales in the next four years. How will pharma take advantage of the opportunity?

March 17, 2010.

Open innovation is sometimes chaotic and often difficult to measure, but getting it right can give firms a real edge now and in the future.

Having a 'maverick' in your company can lead to problems as well as breakthroughs and innovations. Judith Germain outlines the value of harnessing a brilliant but wayward talent.

4 March, 2010

Can the combination with Schering-Plough transform the company from an also-ran to a contender in the big push for market share in the developing world?

Anirban Ghosh and Siddharth Sawhney explain how research informatics tools can advance the speed and success of drug discovery research.

A corporate focus on negotiation can help organizations reap substantial and measurable benefit, writes Alison Morris.

February 26, 2010.

February 18, 2010.

Marketing excellence programmes are popular, important and frequently flawed, says Dr Brian D. Smith

February 16, 2010.

February 10, 2010.

Although representing a huge market, the EU also presents problems that hamper profitability- particularly when it comes to differing price regulations across member states.

January 29, 2010.

January 13, 2010.

Dr Kay Wardle of RSA examines the impact of short-term survival strategies on pre-clinical R&D organizations.

January 06, 2010.

January 04. 2010.

Quintiles' Jim Featherstone asks what the end of the blockbuster generation means for the sales operation?s business model and how pharma should react to the transition.

Reflector reports on how the European pharma commitees and national associations are trying to shape the upcoming pharmaceutical package through informal

With a weak pound being outpaced by the euro, many hospitals are sending drugs to the Continent for higher profits. What can NHS do to stop this practice?